KDR and neoplasm: Although there is evidence that bevacizumab reduces tumor edema, angiogenesis, and disease burden, the use of this agent as well as other VEGFA/VEGFR2-targeting drugs has been followed by adaptive tumor responses in preclinical models and clinical settings [4–8].